BYLINE: Denise Heady
Newswise — Dr. Sanaz Memarzadeh, professor of obstetrics and gynecology and molecular and medical pharmacology on the David Geffen Faculty of Drugs at UCLA and surgeon-scientist within the UCLA Well being Jonsson Complete Most cancers Middle, has obtained two grants totaling $4.1 million to develop superior cell primarily based immune therapies for high-grade serous ovarian cancers which have develop into resistant to traditional therapies.
Excessive-grade serous ovarian most cancers is the most typical and most aggressive sort of ovarian most cancers. Almost all sufferers recognized with this most cancers will relapse after preliminary remedy. Illness recurrence inside six months of platinum-based chemotherapy remedy is categorized as platinum-resistant high-grade serous ovarian most cancers, which is very deadly.
“With the help of those grants, we hope to enhance remedy outcomes for sufferers who’ve restricted remedy choices,” stated Memarzadeh, who can also be director of the G.O. Discovery Lab and a member of the Eli and Edythe Broad Middle of Regenerative Drugs and Stem Cell Analysis at UCLA.
Growing new T-cell receptor therapies
For the primary grant, awarded by the Nationwide Most cancers Institute for $3.4 million, Memarzadeh and a workforce of researchers from UCLA and the Youngsters’s Hospital of Philadelphia want to determine new protein variations in most cancers cells brought on by RNA dysregulation in platinum-resistant ovarian most cancers.
By learning these variations, they hope to determine new targets for immunotherapy, particularly for a kind of remedy known as adoptive T cell remedy. Adoptive T cell remedy is a kind of cell remedy that includes modifying T cells, which is a kind of immune cell, to reinforce their capability to combat most cancers. The investigators hope to engineer T cells with T cell receptors (TCRs) that can particularly acknowledge and kill tumor cells primarily based on the recognized cancer-specific protein variations.
“Adoptive T-cell remedy has demonstrated efficacy in treating sure hematologic malignancies together with leukemia and lymphoma,” stated Memarzadeh. “We’re hopeful that we will uncover new antigens and TCRs that can be utilized to develop efficient therapies for platinum-resistant ovarian most cancers.”
Together with Memarzadeh, the analysis workforce consists of professor Yi Xing from the Youngsters’s Hospital of Philadelphia and the College of Pennsylvania; Dr. Christopher Seet, assistant professor of drugs within the division of hematology-oncology on the David Geffen Faculty of Drugs at UCLA; and Dr. Owen Witte, College Professor of microbiology, immunology and molecular genetics at UCLA.
Activating pure killer cells to assault treatment-resistant most cancers cells
The second grant, which is a $700,000 award from the US Division of Veterans Affairs, helps Memarzadeh’s analysis with a special sort of immune cell known as pure killer (NK) cells to deal with platinum-resistant ovarian most cancers.
These resistant most cancers cells are sometimes enriched with poorly differentiated stem-like cells known as PD-SLCs that harbor distinctive traits that makes them onerous to focus on with conventional therapies like chemotherapy and cytotoxic T-cells. Nevertheless, researchers have discovered that NK cells can efficiently assault PD-SLCs. The issue with NK cells is that their numbers could also be low, and their operate could also be faulty in lots of sufferers, together with girls recognized with ovarian most cancers.
To deal with this situation, a collaborator on the grant Anahid Jewett, professor within the faculty of Dentistry at UCLA, and her workforce developed a brand new methodology to activate and broaden NK cells in giant numbers, creating what are known as supercharged NK (sNK) cells. These supercharged cells aren’t solely sturdy however have been discovered to be functionally superior to peripheral blood NK cells.
On this research, the workforce will check how efficient these sNK cells are, each alone and together with chemotherapy, in focusing on platinum-resistant high-grade serous ovarian most cancers. They may also look to determine biomarkers that point out how nicely the remedy is working to assist predict which sufferers will reply greatest to sNK cell remedy and higher perceive how sNK cells and chemotherapy work collectively to focus on and kill chemo-resistant tumor cells.
Additionally collaborating on this grant is Thomas Graeber, professor of molecular and medical pharmacology on the David Geffen Faculty of Drugs at UCLA; Dr. David Elashoff, professor biostatistics and computational medication at UCLA; and Dr. Michael Lewis within the division of pathology on the West Los Angeles VA hospital. Each Jewett, Graeber and Elashoff are additionally members of the UCLA Well being Jonsson Complete Most cancers Middle.
“By way of our analysis efforts we hope to check new remedy approaches for girls impacted by excessive grade serous ovarian most cancers whereas paving the best way for hopefully life-saving therapies,” stated Memarzadeh.
